Paper36088407
Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections.
Sadyrbaeva-Dolgova S and 5 others. Sci Rep, 2022. Cited by 9 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections. Papers, record 36088407. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36088407
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gram-Negative Bacterial Infections | Major topic |
| Renal Insufficiency | Major topic |
| Colistin | |
| Creatinine | |
| Humans | |
| Incidence | |
| Pseudomonas aeruginosa | |
| Retrospective Studies |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,444,952 | Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. | Clin Microbiol Rev | 2018 | https://conductscience.org/library/papers/29444952 | PubMed |
| 2 | 25,756,417 | Association between colistin dose and development of nephrotoxicity. | Crit Care Med | 2015 | https://conductscience.org/library/papers/25756417 | PubMed |
| 3 | 29,456,043 | Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. | Lancet Infect Dis | 2018 | https://conductscience.org/library/papers/29456043 | PubMed |
| 4 | 31,923,573 | Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/31923573 | PubMed |
| 5 | 22,890,468 | KDIGO clinical practice guidelines for acute kidney injury. | Nephron Clin Pract | 2012 | https://conductscience.org/library/papers/22890468 | PubMed |
| 6 | 16,940,086 | Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16940086 | PubMed |
| 7 | 15,825,037 | Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. | Clin Infect Dis | 2005 | https://conductscience.org/library/papers/15825037 | PubMed |
| 8 | 30,710,469 | International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). | Pharmacotherapy | 2019 | https://conductscience.org/library/papers/30710469 | PubMed |
| 9 | 22,423,120 | High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. | Clin Infect Dis | 2012 | https://conductscience.org/library/papers/22423120 | PubMed |
| 10 | 30,323,035 | New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30323035 | PubMed |
| 11 | 16,280,245 | Nephrotoxicity of intravenous colistin: a prospective evaluation. | Int J Antimicrob Agents | 2005 | https://conductscience.org/library/papers/16280245 | PubMed |
| 12 | 23,357,291 | Tigecycline: an update. | Diagn Microbiol Infect Dis | 2013 | https://conductscience.org/library/papers/23357291 | PubMed |
| 13 | 19,303,668 | [Aminoglycosides and polymyxins]. | Enferm Infecc Microbiol Clin | 2009 | https://conductscience.org/library/papers/19303668 | PubMed |
| 14 | 20,302,384 | Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. | J Phys Chem B | 2010 | https://conductscience.org/library/papers/20302384 | PubMed |
| 15 | 20,045,293 | Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. | Int J Antimicrob Agents | 2010 | https://conductscience.org/library/papers/20045293 | PubMed |
| 16 | 28,011,614 | Dosing guidance for intravenous colistin in critically-ill patients. | Clin Infect Dis | 2017 | https://conductscience.org/library/papers/28011614 | PubMed |
| 17 | 27,624,572 | Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/27624572 | PubMed |
| 18 | 23,357,775 | Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23357775 | PubMed |
| 19 | 19,433,570 | Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19433570 | PubMed |
| 20 | 28,970,161 | The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. | Clin Microbiol Infect | 2018 | https://conductscience.org/library/papers/28970161 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,792,016 | Predictors of In-Hospital Mortality Among Hospitalized Colistin-Treated Patients at a Tertiary Urology-Nephrology Referral Center. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42792016 | PubMed |
| 42,183,845 | Synergistic strategies to rescue the last-resort antibiotic colistin. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/42183845 | PubMed |
| 41,704,330 | Efficacy of inhaled antibiotics in children with ventilator-associated pneumonia: A systematic review and meta-analysis. | J Crit Care Med (Targu Mures) | 2026 | https://conductscience.org/library/papers/41704330 | PubMed |
| 41,007,816 | Antimicrobial Resistance of Non-Fermenting Gram-Negative Bacilli in a Multidisciplinary Hospital in Romania. | Biomedicines | 2025 | https://conductscience.org/library/papers/41007816 | PubMed |
| 40,880,630 | Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/40880630 | PubMed |
| 40,787,933 | Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen. | Clin Microbiol Rev | 2025 | https://conductscience.org/library/papers/40787933 | PubMed |
| 40,781,278 | Acute kidney injury of intravenous colistin sulfate compared with colistimethate sodium: a real-world, retrospective cohort study. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/40781278 | PubMed |
| 37,110,322 | The Challenge of Bacteremia Treatment due to Non-Fermenting Gram-Negative Bacteria. | Microorganisms | 2023 | https://conductscience.org/library/papers/37110322 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36088407
GET https://conductscience.org/api/papers/v1/36088407/references?page=2